B7‑33 is an experimental peptide that has only been examined in animal‑only preclinical studies, with no FDA‑approved indication and no documented off‑label uses in the community. Users who obtain it do so through compounding pharmacies and typically follow unstandardized dosing regimens drawn from the limited research literature, but there is no established protocol; the sole practical consideration is that any human use is entirely off‑label.
Data last updated
Measured on 3 of 6 axes
Evidence shape
B7-33 currently exists strictly within the realm of animal-only research, with no published human trials or clinical data available. The existing literature is limited to preclinical and mechanistic studies, providing no evidence of safety or efficacy in human subjects. Because there are zero registered trials and no completed human studies, the peptide lacks the necessary data to support any therapeutic application. This absence of human-grade evidence means that all current understanding of the peptide remains confined to laboratory models.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How B7-33 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Based on two community reports, doses range from 300 mcg taken daily to 2.5 mg with no stated frequency, both given subcutaneously.